Literature DB >> 15586228

Functional expression of TWEAK in human colonic adenocarcinoma cells.

Tomoyuki Kawakita1, Katsuya Shiraki, Yutaka Yamanaka, Yumi Yamaguchi, Yukiko Saitou, Naoyuki Enokimura, Norihiko Yamamoto, Hiroshi Okano, Kazushi Sugimoto, Kazumoto Murata, Takeshi Nakano.   

Abstract

The TNF-like weak inducer of apoptosis (TWEAK) can induce diverse cellular responses, including cell death, inflammation, migration, and proliferation in various transformed cell lines. We investigated TWEAK sensitivity, TWEAK effects on nuclear factor-kappaB activation, and expression of TWEAK in the HT-29, LS180, SK-CO-1 and SW480 human colonic adenocarcinoma cell lines, all of which express the TWEAK receptor (Fn14). TWEAK alone induced cell death in SW480 cells and induced cell death of HT-29 cells after addition of IFN-gamma, actinomycin D or cycloheximide. TWEAK did not affect cell viability of LS-180 or SK-CO-1 cells. Activation of NF-kappaB was not obviously influenced by TWEAK in any of the cell lines. All four human colonic adenocarcinoma cell lines constitutively expressed TWEAK mRNA, protein and membrane-bound TWEAK antigen, as detected by RT-PCR, Western blotting and flow cytometry. Stimulation by an anticancer drug (camptothecin) augmented cell surface expression of TWEAK and all human colonic adenocarcinoma tissue samples studied (n=59) demonstrated positive staining for TWEAK antigen. Soluble TWEAK was detected in culture medium of these cell lines by ELISA and conditioned medium from SW480 cells incubated with anti-TWEAK antibody significantly inhibited endothelial cell tube formation in Matrigels. Thus, functional expression of TWEAK from human colonic adenocarcinoma cells may contribute to neovascularization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15586228

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  17 in total

Review 1.  The TWEAK-Fn14 system as a potential drug target.

Authors:  Harald Wajant
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

2.  Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway.

Authors:  Sharron A N Brown; Arundhati Ghosh; Jeffrey A Winkles
Journal:  J Biol Chem       Date:  2010-04-12       Impact factor: 5.157

3.  Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer.

Authors:  Ryo Yoriki; Satoru Akashi; Masayuki Sho; Takeo Nomi; Ichiro Yamato; Kiyohiko Hotta; Tomoyoshi Takayama; Sohei Matsumoto; Kohei Wakatsuki; Kazuhiro Migita; Hideo Yagita; Yoshiyuki Nakajima
Journal:  Exp Ther Med       Date:  2010-12-02       Impact factor: 2.447

4.  Increased serum tumor necrosis factor receptor-associated factor-6 expression in patients with non-metastatic triple-negative breast cancer.

Authors:  Cemil Bilir; Huseyin Engin; Murat Can; Sevili Likhan; Derya Demirtas; Fatih Kuzu; Taner Bayraktaroglu
Journal:  Oncol Lett       Date:  2015-04-01       Impact factor: 2.967

5.  Regulation of tumor necrosis factor-like weak inducer of apoptosis receptor protein (TWEAKR) expression by Kaposi's sarcoma-associated herpesvirus microRNA prevents TWEAK-induced apoptosis and inflammatory cytokine expression.

Authors:  Johanna R Abend; Thomas Uldrick; Joseph M Ziegelbauer
Journal:  J Virol       Date:  2010-09-15       Impact factor: 5.103

6.  Development of an Fn14 agonistic antibody as an anti-tumor agent.

Authors:  Jennifer S Michaelson; Aldo Amatucci; Rebecca Kelly; Lihe Su; Ellen Garber; Eric S Day; Lisa Berquist; Sandy Cho; You Li; Michael Parr; Laure Wille; Pascal Schneider; Kathleen Wortham; Linda C Burkly; Yen-Ming Hsu; Ingrid B J K Joseph
Journal:  MAbs       Date:  2011-07-01       Impact factor: 5.857

Review 7.  TWEAK and the central nervous system.

Authors:  Manuel Yepes
Journal:  Mol Neurobiol       Date:  2007-06       Impact factor: 5.590

Review 8.  The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting.

Authors:  Jeffrey A Winkles
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

9.  The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC.

Authors:  Xuehao Li; Xin Zhang; Chunlu Yang; Su Cui; Qiming Shen; Shun Xu
Journal:  Cell Cycle       Date:  2018-08-02       Impact factor: 4.534

Review 10.  Activation of stem cells in hepatic diseases.

Authors:  T G Bird; S Lorenzini; S J Forbes
Journal:  Cell Tissue Res       Date:  2007-11-29       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.